Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gibbs

Showing results (401-410 of 427) with videos related to

Pageof 43
Sort By:
Communications Biology|June 5, 2025
Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell linesIan Y Luk, Jennifer K Mooi, Dmitri Mouradov, et al.
JAMA Oncology|January 29, 2026
Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE TrialSuzanne G Orchard, Galina Polekhina, John Zalcberg, et al.
Cancer Research|May 12, 2011
PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesisAnuratha Sakthianandeswaren, Michael Christie, Carla D'Andreti, et al.
Journal of the National Cancer Institute|August 12, 2020
Effect of Aspirin on Cancer Incidence and Mortality in Older AdultsJohn J McNeil, Peter Gibbs, Suzanne G Orchard, et al.
Nature Medicine|October 20, 2025
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trialJeanne Tie, Yuxuan Wang, Jonathan M Loree, et al.
Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.
Cancer Discovery|October 25, 2023
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer CellsZilu Wang, Matteo Burigotto, Sabrina Ghetti, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 23, 2019
Baseline Characteristics of Participants in the ASPREE (Aspirin in Reducing Events in the Elderly) StudyJohn J McNeil, Robyn L Woods, Mark R Nelson, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 23, 2017
Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) StudyJohn J McNeil, Robyn L Woods, Mark R Nelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGuy A van Hazel, Volker Heinemann, Navesh K Sharma, et al.
Pageof 43

Showing results (401-410 of 427) with videos related to

Sort By:
Pageof 43
Communications Biology|June 5, 2025
Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell linesIan Y Luk, Jennifer K Mooi, Dmitri Mouradov, et al.
JAMA Oncology|January 29, 2026
Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE TrialSuzanne G Orchard, Galina Polekhina, John Zalcberg, et al.
Cancer Research|May 12, 2011
PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesisAnuratha Sakthianandeswaren, Michael Christie, Carla D'Andreti, et al.
Journal of the National Cancer Institute|August 12, 2020
Effect of Aspirin on Cancer Incidence and Mortality in Older AdultsJohn J McNeil, Peter Gibbs, Suzanne G Orchard, et al.
Nature Medicine|October 20, 2025
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trialJeanne Tie, Yuxuan Wang, Jonathan M Loree, et al.
Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.
Cancer Discovery|October 25, 2023
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer CellsZilu Wang, Matteo Burigotto, Sabrina Ghetti, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 23, 2019
Baseline Characteristics of Participants in the ASPREE (Aspirin in Reducing Events in the Elderly) StudyJohn J McNeil, Robyn L Woods, Mark R Nelson, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 23, 2017
Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) StudyJohn J McNeil, Robyn L Woods, Mark R Nelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGuy A van Hazel, Volker Heinemann, Navesh K Sharma, et al.
Pageof 43